A $18B market built on a cost model that no longer holds.
Every enzymatic CGM unit sold depends on a replacement in 14 days. The optical platform eliminates that dependency at the device level — compressing COGS while capturing lifetime monitoring revenue.
The numbers behind the thesis.
$18B+
26+
589M+
Global CGM TAM
Annual Sensor Replacements
Addressable Population
The global continuous glucose monitoring market, structurally dependent on high-frequency consumable repurchase — a model the optical platform exits entirely.
Per user, per year. Each replacement is a recurring COGS event that the zero-replacement architecture converts into a single lifetime hardware transaction.
Diabetic and pre-diabetic individuals globally. Skin-tone agnostic optical performance opens segments where enzymatic accuracy is clinically insufficient.
Enzymatic vs. Optical
One unit. Lifetime revenue. No consumable drag.
Enzymatic CGM revenue is consumable revenue: margins are structurally capped by recurring per-unit material cost. The optical platform captures the same monitoring revenue without the replacement cycle eroding gross margin at scale.
Enzymatic: 26 sensor purchases annually. Each carries material, logistics, and waste-stream costs that compound per-user.
Optical: single device acquisition. Zero replacement SKUs. ISF lag eliminated at the architecture level — not managed, removed.
For an acquirer integrating this as a first-party hardware component, that delta represents a permanent structural margin advantage — not a product feature.
Skin-tone agnostic performance is a market expansion.
Enzymatic CGM accuracy degrades across darker skin tones — a known limitation the category has accepted. Optical performance is skin-tone agnostic by architecture, opening a quantifiable population segment that current platforms cannot serve at clinical accuracy.